NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
Patient Education: Belantamab Mafodotin-blmf (Blenrep) Antibody Drug Conjugate for Multiple Myeloma
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
SCIP & SAVOR FOR A CURE - A Fundraising Hosted By: Fatima and Jimmy Scipione - Sat Oct 15th, 2022
The Binding Site: Freelite Overview
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
IMF - International Myeloma Foundation: Patient Handbook 2022
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
NCT05256446: AMG 701 Expanded Access Program